132 related articles for article (PubMed ID: 38780360)
1. Functional impairment of chronic migraine with medication overuse: Secondary analysis from the Medication Overuse Treatment Strategy (MOTS) trial.
Shao SC; Hentz J; Shank P; Leonard M; Dodick DW; Schwedt TJ
Headache; 2024 Jun; 64(6):632-642. PubMed ID: 38780360
[TBL] [Abstract][Full Text] [Related]
2. Headache characteristics and burden from chronic migraine with medication overuse headache: Cross-sectional observations from the Medication Overuse Treatment Strategy trial.
Schwedt TJ; Hentz JG; Sahai-Srivastava S; Spare NM; Martin VT; Treppendahl C; Digre K; Bennett NL; Birlea M; Watson D; Murinova N; Robert T; Dodick DW;
Headache; 2021 Feb; 61(2):351-362. PubMed ID: 33432635
[TBL] [Abstract][Full Text] [Related]
3. Determinants of pain interference and headache impact in patients who have chronic migraine with medication overuse: Results from the MOTS trial.
Schwedt TJ; Sahai-Srivastava S; Murinova N; Birlea M; Ahmed Z; Digre K; Lopez K; Mullally W; Blaya MT; Pippitt K; Cutrer FM; DeLange J; Schecht H; Rizzoli P; Lane J; Wald J; Cortez MM; Martin VT; Spare NM; Hentz JG; Robert T; Dodick DW;
Cephalalgia; 2021 Sep; 41(10):1053-1064. PubMed ID: 33938249
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the Psychometric Properties of the Migraine Functional Impact Questionnaire (MFIQ).
Kawata AK; Hareendran A; Shaffer S; Mannix S; Thach A; Desai P; Mikol DD; Ortmeier B; Bayliss M; Buse DC
Headache; 2019 Sep; 59(8):1253-1269. PubMed ID: 31168803
[TBL] [Abstract][Full Text] [Related]
5. Patient-Centered Treatment of Chronic Migraine With Medication Overuse: A Prospective, Randomized, Pragmatic Clinical Trial.
Schwedt TJ; Hentz JG; Sahai-Srivastava S; Murinova N; Spare NM; Treppendahl C; Martin VT; Birlea M; Digre K; Watson D; Leonard M; Robert T; Dodick DW;
Neurology; 2022 Apr; 98(14):e1409-e1421. PubMed ID: 35169011
[TBL] [Abstract][Full Text] [Related]
6. Reducing the physical, social, and emotional impact of episodic migraine: Results from erenumab STRIVE and ARISE phase III randomized trials.
Kawata AK; Ladd MK; Lipton RB; Buse DC; Bensink M; Shah S; Hareendran A; Mannix S; Mikol D
Headache; 2022 Feb; 62(2):159-168. PubMed ID: 35137394
[TBL] [Abstract][Full Text] [Related]
7. Development of a New Tool for Evaluating the Benefit of Preventive Treatments for Migraine on Functional Outcomes - The Migraine Functional Impact Questionnaire (MFIQ).
Hareendran A; Skalicky A; Mannix S; Lavoie S; Desai P; Bayliss M; Thach AV; Mikol DD; Buse DC
Headache; 2018 Nov; 58(10):1612-1628. PubMed ID: 30374958
[TBL] [Abstract][Full Text] [Related]
8. Prevention of medication overuse and medication overuse headache in patients with migraine: a randomized, controlled, parallel, allocation-blinded, multicenter, prospective trial using a mobile software application.
Diener HC; Donoghue S; Gaul C; Holle-Lee D; Jöckel KH; Mian A; Schröder B; Kühl T
Trials; 2022 May; 23(1):382. PubMed ID: 35546412
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse in the Randomized, Double-Blind, Phase 3 PROGRESS Trial.
Goadsby PJ; Friedman DI; Holle-Lee D; Demarquay G; Ashina S; Sakai F; Neel B; Gandhi P; Dabruzzo B; Smith JH; Liu Y; Trugman JM
Neurology; 2024 Jul; 103(2):e209584. PubMed ID: 38924724
[TBL] [Abstract][Full Text] [Related]
10. Disability in chronic migraine patients with medication overuse: treatment effects at 1-year follow-up.
Grazzi L; Andrasik F; D'Amico D; Usai S; Kass S; Bussone G
Headache; 2004; 44(7):678-83. PubMed ID: 15209690
[TBL] [Abstract][Full Text] [Related]
11. Botulinum toxin type A and acute drug costs in migraine with triptan overuse.
Christie SN; Giammarco R; Gawel M; Mackie G; Gladstone J; Becker WJ
Can J Neurol Sci; 2010 Sep; 37(5):588-94. PubMed ID: 21059503
[TBL] [Abstract][Full Text] [Related]
12. Lifetime history of an anxiety or depression disorder and adherence to medications used for the acute treatment of migraine.
Butler N; Snyder IC; Korn TG; Nicholson RA; Robbins MS; Seng EK
Headache; 2023 Mar; 63(3):368-376. PubMed ID: 36752627
[TBL] [Abstract][Full Text] [Related]
13. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.
Diener HC; Bussone G; Van Oene JC; Lahaye M; Schwalen S; Goadsby PJ;
Cephalalgia; 2007 Jul; 27(7):814-23. PubMed ID: 17441971
[TBL] [Abstract][Full Text] [Related]
14. [Botulinum toxin type A (Relatox) in transition from medication overuse to non-overuse status in patients with chronic migraine: a subgroup analysis of phase IIIb randomized single-blind multicenter active-controlled parallel-group trial].
Artemenko AR; Abramov VG; Bozhenkina TV; Konovalova ZN; Korenko AN; Krasavina DA; Kurenkov AL; Latysheva NV; Naprienko MV; Orlova OR; Filatova EG; Shevchenko VS; Iakovleva PN
Zh Nevrol Psikhiatr Im S S Korsakova; 2023; 123(11):64-74. PubMed ID: 37994890
[TBL] [Abstract][Full Text] [Related]
15. Complete withdrawal is the most feasible treatment for medication-overuse headache: A randomized controlled open-label trial.
Engelstoft IMS; Carlsen LN; Munksgaard SB; Nielsen M; Jensen RH; Bendtsen L
Eur J Pain; 2019 Jul; 23(6):1162-1170. PubMed ID: 30793412
[TBL] [Abstract][Full Text] [Related]
16. Impact of coronavirus disease 2019 (COVID-19) pandemic on patients with migraine: a web-based survey study.
Al-Hashel JY; Ismail II
J Headache Pain; 2020 Sep; 21(1):115. PubMed ID: 32972360
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study.
Schwedt TJ; Alam A; Reed ML; Fanning KM; Munjal S; Buse DC; Dodick DW; Lipton RB
J Headache Pain; 2018 May; 19(1):38. PubMed ID: 29797100
[TBL] [Abstract][Full Text] [Related]
18. The role of personality, disability and physical activity in the development of medication-overuse headache: a prospective observational study.
Mose LS; Pedersen SS; Debrabant B; Jensen RH; Gram B
J Headache Pain; 2018 May; 19(1):39. PubMed ID: 29802536
[TBL] [Abstract][Full Text] [Related]
19. Mindfulness and pharmacological prophylaxis after withdrawal from medication overuse in patients with Chronic Migraine: an effectiveness trial with a one-year follow-up.
Grazzi L; Sansone E; Raggi A; D'Amico D; De Giorgio A; Leonardi M; De Torres L; Salgado-García F; Andrasik F
J Headache Pain; 2017 Dec; 18(1):15. PubMed ID: 28161874
[TBL] [Abstract][Full Text] [Related]
20. Low cognitive reserve is associated with chronic migraine with medication overuse and poor quality of life.
Gómez-Beldarrain M; Anton-Ladislao A; Aguirre-Larracoechea U; Oroz I; García-Moncó JC
Cephalalgia; 2015 Jul; 35(8):683-91. PubMed ID: 25304767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
